Biopharmaceutical company HedgePath Pharmaceuticals Inc (OTCQB:HPPI) announced on Monday that it proposes to change its name to INHIBITOR Therapeutics as well as a change its the ticker symbol for common and preferred stock to 'INTI' from 'HPPI'.

Both the corporate name change and ticker symbol change are expected to be effective with the opening of trading on 20 August 2019.

Following the corporate name change, INHIBITOR will launch a new website (http://www.inhibitortx.com) to showcase INHIBITOR's vision and development strategy for SUBA-Itraconazole, a proprietary formulation of the FDA approved anti-fungal drug itraconazole designed to enable improved bioavailability compared to conventional itraconazole when used as an anti-cancer treatment, as well as novel compounds that inhibit upstream targets of the Hedgehog Pathway as treatments for cancer and non-cancerous proliferation disorders.

In addition, SUBA-Itraconazole is manufactured by Mayne Pharma under current Good Manufacturing Practice standards for INHIBITOR's use in clinical trials. An affiliate of Mayne Pharma is INHIBITOR's majority stockholder and licensor of the SUBA-Itraconazole technology.

Concurrently, INHIBITOR will conduct end of Phase 2 Meeting with FDA in the fourth quarter of 2019 as well as file IND for Phase 2b clinical trial of SUBA-Itraconazole in prostate cancer. It renews and expands exclusive worldwide option agreement with the University of Connecticut for novel compounds that inhibit upstream targets of the Hedgehog Pathway.

Headquartered in Tampa, Florida, INHIBITOR Therapeutics Inc (OTCQB:INTI) is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders. HedgePath is the exclusive US licensee of SUBA-Itraconazole in certain fields.